Compare ADMA Biologics Inc (ADMA) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Match Group Inc — how do they compare? ADMA Biologics Inc trades at $9.19 (market cap $2.13B), while Match Group Inc trades at $37.86 (market cap $9.14B). The key difference: Match Group Inc is far larger — about 4.3× ADMA Biologics Inc's market cap, and Match Group Inc pays a 2.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MTCH | |
|---|---|---|
Market Cap | $2.13B | $9.14B |
Sector | Health | Media |
52-Week High | $20.38 | $39.18 |
52-Week Low | $7.60 | $28.90 |
Enterprise Value | $2.20B | $12.09B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MTCH trades at $39.18, up 3.38% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 73.8% gross margin and 18.83% net income margin, supported by positive cash flow trends. Recent news highlights a turnaround narrative, with Tinder stabilizing and Hinge driving growth.
Outlook is positive with a consensus price target of $41.63, implying 6.3% upside. Risks include high debt levels and user decline concerns. Analysts are bullish (53% buy ratings), but investors should monitor execution on growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
